Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Forum
  • Nora AI
  • About Us
    • Our Coverage
    • Team
Press release

Medivir's CEO to BioStock: "The IND approval is a very important milestone"

Medivir

Medivir has secured FDA approval to proceed with a phase IIb trial evaluating fostrox in combination with Lenvima for second-line treatment of advanced liver cancer. The trial will evaluate the combination's effect compared to Lenvima alone, building on encouraging phase Ib/IIa results, aiming to bevome the first, approved treatment option in second-line liver cancer. We reached out to CEO Jens Lindberg for a comment.

Read the full interview with Jens Lindberg at biostock.se:

https://www.biostock.se/en/2024/12/medivirs-ceo-the-ind-approval-is-a-very-important-milestone/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/

Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.